Examples of molecularly targeted therapies include inhibitors of mutant EGFR and ALK in lung cancers; inhibitors of BRAF in melanomas; or inhibitors of mutant EGFR and HER2 in breast cancer1–3. Here, EGFR is linked to melanoma.